TickerFacts.

Axsome Therapeutics, Inc. (AXSM): Revenue

Annual figures by period end, from SEC filings.

$638.50M
Year ended 2025-12-31
$776.57M
Trailing 12 months to 2026-06-30
+133.7%
3-year compound annual growth
2022-12-31: $50.04M2023-12-31: $270.60M2024-12-31: $385.69M2025-12-31: $638.50M$638.50M
2022-12-31 Revenue (USD) 2025-12-31
Period endedRevenueChange YoYSource filing
2025-12-31$638.50M+65.5%2026-02-23, From 2025-01-01
2024-12-31$385.69M+42.5%2026-02-23, From 2024-01-01
2023-12-31$270.60M+440.8%2026-02-23, From 2023-01-01
2022-12-31$50.04Mn/a2025-02-18, From 2022-01-01

Revenue at similar companies

Companies with the same SEC industry code (Pharmaceutical Preparations), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

CompanyYear endedRevenueChange YoY
Axsome Therapeutics, Inc. (AXSM)2025-12-31$638.50M+65.5%
TG Therapeutics, Inc. (TGTX)2025-12-31$616.29M+87.3%
Opko Health, Inc. (OPK)2025-12-31$606.88M-14.9%
Insmed Inc (INSM)2025-12-31$606.42M+66.7%
Ultragenyx Pharmaceutical Inc. (RARE)2025-12-31$673.00M+20.2%
Kiniksa Pharmaceuticals International, plc (KNSA)2025-12-31$677.56M+60.1%
Supernus Pharmaceuticals, Inc. (SUPN)2025-12-31$718.95M+8.6%
Amphastar Pharmaceuticals, Inc. (AMPH)2025-12-31$719.89M-1.7%
Organogenesis Holdings Inc. (ORGO)2025-12-31$564.17M+17.0%

Compare AXSM, TGTX, OPK, INSM side by side · Screen every company in Pharmaceutical Preparations ↗